Q2 2025 Earnings Call Transcript August 12, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.32. Operator: Good morning, ladies and gentlemen, and ...

Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

Altimmune (NASDAQ:ALT) shares surge 8% post-promising Q2 results, driven by pemvidutide's success in metabolic and liver conditions. Read more here.

GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic ...

Fatty liver disease symptoms change as the disease progresses. You may not have symptoms early on, but upper-right abdominal ...

Altimmune ( ($ALT) ) has released its Q2 earnings. Here is a breakdown of the information Altimmune presented to its investors. Altimmune, Inc. is ...

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise ...

Aerobic exercise and a high capacity for exercise may protect against metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, by increasing the ...

The liver is a vital organ in flushing out toxins from our bodies. Here, we break down the best foods to keep it healthy.

Liver cancer is the sixth most common cancer in the world, with around 870,000 cases in 2022. That’s projected to increase to 1.52 million cases in 2050, the new report found, if no changes are ...